STSA

Satsuma Pharmaceuticals, Inc. [STSA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

STSA Stock Summary

In the News

STSA Financial details

Company Rating
-
Market Cap
36.47M
Income
-63.33M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
25
Optionable
No
Shortable
Yes
Earnings
07 Aug 2023
P/E
-0.58
Forward P/E
-
PEG
-0.51
P/S
-
P/B
0.97
P/C
-
P/FCF
-0.74
Quick Ratio
7.09
Current Ratio
7.44
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.96
EPS next Y
-
EPS next Q
-
EPS this Y
22.73%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-55.88%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-146%
ROE
755%
ROC
-1.76%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.59-8.08
52W High
-
52W Low
-
RSI
-
Rel Volume
1.65
Avg Volume
1.11M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.101764
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
TL0.DE
VFINX
0YXG.L
GOOGL
EMBASSY.NS
Same Sector
3839.HK
LH
CRBU
NEPH
TLSA
Check Those
STRT
SHISX
SHG.L
GFASY
CBKPP
Similar Market Cap
WTEE.DE
EARN.TO
FAI.TO
PREM.L
LYQK.DE

Company Profile

Healthcare Biotechnology
  • Volume Average 1.11M
  • Market Capitalization 36.47M
  • Employee 25
  • CEO Mr. John A. Kollins MBA
  • Headquarters South San Francisco,CA,US
  • IPO Date 2019-09-13
  • Website https://www.satsumarx.com

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.